Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced the launch of an additional qPCR array for sensitive and specific quantification of 749 mouse and rat microRNAs.

With the launch of the new rodent qPCR array, Exiqon now offers two qPCR arrays for mouse and rat microRNAs in addition to the two qPCR arrays for human microRNAs. All qPCR arrays are based on LNA™ enhanced microRNA PCR primer sets and comprise more than 1,500 pre-validated assays making the qPCR assay offering the most comprehensive in the market.

“We have seen an increasing demand for a second mouse and rat qPCR array for genome wide screening and we are happy to have this product on the market today” said Senior Vice President Sales & Marketing, Dr. Henrik M. Pfundheller and added: “All assays are validated against synthetic miRNA targets and tested for specificity and linear dynamic range of a minimum of 5 logs”.

The extreme sensitivity obtained by inclusion of LNA™ in the PCR primers enables accurate microRNA profiling based on as little as 50 ?l serum.

Exiqon’s product line for microRNA qPCR also includes custom Pick & Mix ready-to-use 96- and 384-well panels, individual pre-validated and custom designed primer sets as well as RT and Master Mix kits and a qPCR data analysis software package.

About Exiqon

Exiqon’s products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market’s leading providers of miRNA research products for miRNA analysis in cells and bodyfluids. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to target new medicines based on miRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.